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Abstract The aim of this study was to characterize the
influence of WIN 55,212-2 (WIN—a non-selective can-
nabinoid CB1 and CB2 receptor agonist) on the anticon-
vulsant effects of various classical antiepileptic drugs
(clobazam, clonazepam, phenobarbital and valproate) in
the mouse 6 Hz-induced psychomotor seizure model.
Limbic (psychomotor) seizure activity was evoked in
albino Swiss mice by a current (32 mA, 6 Hz, 3 s stimulus
duration) delivered via ocular electrodes. Drug-related
adverse effects were ascertained by use of the chimney test
(evaluating motor performance), step-through passive
avoidance task (assessing learning) and grip-strength test
(evaluating skeletal muscular strength). Total brain con-
centrations of antiepileptic drugs were measured by fluo-
rescence polarization immunoassay to ascertain any
pharmacokinetic contribution to the observed antiseizure
effect. Results indicate that WIN (5 mg/kg, administered
intraperitoneally) significantly enhanced the anticonvulsant
action of clonazepam (P \ 0.001), phenobarbital
(P \ 0.05) and valproate (P \ 0.05), but not that of clo-
bazam in the mouse 6 Hz model. Moreover, WIN (2.5 mg/
kg) significantly potentiated the anticonvulsant action of
clonazepam (P \ 0.01), but not that of clobazam, pheno-
barbital or valproate in the 6 Hz test in mice. None of the
investigated combinations of WIN with antiepileptic drugs
was associated with any concurrent adverse effects with
regard to motor performance, learning or muscular
strength. Pharmacokinetic experiments revealed that WIN
had no impact on total brain concentrations of antiepileptic
drugs in mice. These preclinical data would suggest that
WIN in combination with clonazepam, phenobarbital and
valproate is associated with beneficial anticonvulsant
pharmacodynamic interactions in the mouse 6 Hz-induced
psychomotor seizure test.
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Accumulating experimental evidence indicates that one of
the synthetic cannabimimetic compounds [i.e., WIN
55,212-2 mesylate (WIN)—a highly potent non-selective
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cannabinoid CB1 and CB2 receptor agonist] potentiated the
anticonvulsant activity of some classical antiepileptic drugs
(i.e., diazepam, carbamazepine, phenytoin, phenobarbital
and valproate) and second-generation antiepileptic drugs
(i.e., lamotrigine, pregabalin and topiramate) in the mouse
maximal electroshock-induced tonic seizure (MES) model
(Luszczki et al. 2011b, 2013; Naderi et al. 2008). WIN also
enhanced the anticonvulsant activity of ethosuximide,
phenobarbital and valproate in the mouse pentylenete-
trazole-induced clonic seizure (PTZ) model (Luszczki et al.
2011a).
Considering the above-mentioned facts, it was of
importance to continue experiments and determine the
influence of WIN on the anticonvulsant action of some
classical antiepileptic drugs (i.e., clonazepam, clobazam,
phenobarbital and valproate) in the mouse 6 Hz-induced
psychomotor seizure model. Low-frequency (6 Hz), long-
duration (3 s) electrical stimulation in mice produces sei-
zures characterized by immobility, focal clonus, and
automatic behaviors reminiscent of human limbic epilepsy
(Barton et al. 2001). Noteworthy, in this experimental
model, one can readily assess the anticonvulsant potential
of agents and compounds possessing the anticonvulsant
properties, as well as determine their effects on antiepi-
leptic drugs, effective in suppressing limbic seizures in
humans (Barton et al. 2001).
We sought, therefore, to determine whether WIN would
enhance the protective action of the selected classical
antiepileptic drugs against limbic seizures in the mouse
6 Hz-induced psychomotor seizure model. Additionally, to
determine the acute adverse-effect profiles for the combi-
nations of WIN with clonazepam, clobazam, phenobarbital
and valproate, the chimney test (a measure of motor per-
formance impairment), the step-through passive avoidance
task (a measure of learning deficits), and the grip-strength
test (a measure of skeletal muscular strength impairment)
were used. Finally, total brain antiepileptic drug concen-
trations were measured with fluorescence polarization
immunoassay to ascertain whether any observed significant
effects were consequent to a pharmacodynamic and/or a
pharmacokinetic interaction.
Materials and methods
Animals and experimental conditions
All experiments were performed on adult male Swiss mice
weighing 22–26 g. The animals were purchased from a
licensed breeder (J. Kolacz, Warszawa, Poland). The mice
were kept in colony cages with free access to food (chow
pellets, Agropol S.J., Motycz, Poland), and tap water under
standardized housing conditions (natural light–dark cycle,
temperature of 21 ± 1 C, relative humidity of 55 ± 5 %).
After 7 days of adaptation to laboratory conditions, the
animals were randomly assigned to experimental groups
consisting of eight mice per group. Each mouse was used
only once. All tests were performed between 9.00 and
15.00. Procedures involving animals and their care were
conducted in conformity with current European Commu-
nities Council Directive of 24 November 1986 (86/609/
EEC) and Polish legislation on animal experimentation.
Additionally, all efforts were made to minimize animal
suffering and to use only the number of animals necessary
to produce reliable scientific data. The experimental pro-
tocols and procedures listed were approved by the Second
Local Ethics Committee at the University of Life Sciences
in Lublin (License Nos.: 86/2009, 24/2011, 17/2012) and
conformed with the Guide for the Care and Use of Labo-
ratory Animals.
Drug administration
The following drugs were used in this study: clobazam
(Frisium, Sanofi-Aventis Deutschland GmbH, Frankfurt
am Main, Germany), clonazepam (Polfa, Warszawa,
Poland), phenobarbital (Polfa, Krako´w, Poland), valproate
(magnesium salt—kindly donated by ICN-Polfa S.A.,
Rzeszo´w, Poland), and WIN ((R)-(?)-[2,3-dihydro-5-
methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthalenylmethanone mesylate; To-
cris Bioscience, Bristol, UK). All drugs, except for val-
proate and WIN, were suspended in a 1 % solution of
Tween 80 (Sigma-Aldrich, St. Louis, MO, USA) in dis-
tilled water, while valproate and WIN were dissolved in
distilled water only. All drugs were administered intra-
peritoneally (i.p.) as a single injection in a volume of 5 ml/
kg body weight. Fresh drug solutions were prepared on
each day of experimentation and administered as follows:
clonazepam—15 min, WIN—20 min, clobazam and val-
proate—30 min and phenobarbital—60 min before initia-
tion of psychomotor seizures evoked by 6 Hz corneal
electrical stimulation, evaluation of motor coordination,
grip-strength and learning tests, as well as before brain
sampling for the measurement of antiepileptic drug con-
centrations. The pretreatment times before testing of the
antiepileptic drugs were based on information about their
biological activity from the literature and our previous
experiments (Luszczki et al. 2009, 2010). The times to the
peak of maximum anticonvulsant effects for all antiepi-
leptic drugs were used as the reference times in all
behavioral tests and pharmacokinetic estimation of total
brain antiepileptic drug concentrations. The route of i.p.
administration of WIN and the pretreatment time before
testing of its anticonvulsant effect were based on infor-
mation from previous experiments (Naderi et al. 2008).
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The control animals received an equivalent volume of
vehicle (1 % Tween 80).
The Six-Hertz (6 Hz) psychomotor seizure model
Psychomotor (limbic) seizures were induced via corneal
stimulation (6 Hz, 0.2 ms rectangular pulse width, 32 mA,
3 s duration) delivered by an S48 Square Pulse Stimulator
and CCU1 Constant Current Unit (Grass Technologies,
West Warwick, RI, USA). Ocular anesthetic (0.5 % solu-
tion of tetracaine hydrochloride) was applied to the mouse
corneas 1 min before stimulation. Animals were manually
restrained and released immediately following the stimu-
lation and observed for the presence or absence of seizure
activity. Before stimulation, the corneal electrodes were
wetted with saline to provide good electrical contact.
Immediately following stimulation, mice were placed
separately in Plexiglas cages (25 9 15 9 10 cm) for
behavioral observation. Following the stimulation, the
animals exhibited a ‘‘stunned’’ posture associated with
rearing and automatic movements that lasted from 60 to
120 s in untreated animals. The low-frequency (6 Hz)
long-duration (3 s) seizures were characterized by immo-
bility or stun, jaw and forelimb clonus, twitching of the
vibrissae, and an elevated tail or Straub-tail (Barton et al.
2001; Brown et al. 1953). Animals resumed their normal
exploratory behavior after the seizure. The experimental
endpoint was protected against the seizure: an animal was
considered to be protected if it resumed its normal
exploratory behavior within 10 s after stimulation. Pro-
tection in the 6 Hz model was defined as the absence of a
seizure. Mice not experiencing seizures exhibited normal
exploratory behavior when placed in the cages (Brown
et al. 1953). In the present study, to determine median
effective doses (ED50 values) of antiepileptic drugs, the
drugs were administered i.p. at the following dose ranges:
clobazam, 0.5–4 mg/kg; clonazepam, 0.001–0.05 mg/kg;
phenobarbital, 4–20 mg/kg; and valproate, 50–150 mg/kg.
These antiepileptic drug doses suppressed psychomotor
seizures in 10–90 % of mice subjected to the 6 Hz psy-
chomotor seizure test. Using the log-probit method, the
median effective doses (ED50 values) were determined
using a minimum of eight mice per dose (Litchfield and
Wilcoxon 1949), after which mice were euthanized by CO2
narcosis.
Measurement of total brain antiepileptic drug
concentrations
Pharmacokinetic evaluation of total brain antiepileptic drug
concentrations was performed only for those combinations
of WIN with antiepileptic drugs, whose anticonvulsant
effect in the 6 Hz test was significantly greater than that for
control (an antiepileptic drug ? vehicle-treated) animals.
Thus, the measurement of total brain concentrations of
clonazepam, phenobarbital and valproate was undertaken
at the doses, which corresponded to their ED50 values from
the 6 Hz-induced psychomotor seizure test. Mice were
killed by decapitation at times reflecting the peak of
maximum anticonvulsant effects for the drugs in the 6 Hz
psychomotor test. The whole brains of mice were removed
from skulls, weighed, harvested and homogenized using
Abbott buffer (1:2 wt/vol) in an Ultra-Turrax T8 homog-
enizer (IKA Werke, Staufen, Germany). The homogenates
were centrifuged at 10,000g for 10 min The supernatant
samples (75 ll) were analyzed by fluorescence polarization
immunoassay for clonazepam, phenobarbital and valproate
content using a TDx analyzer and reagents exactly as
described by the manufacturer (Abbott Laboratories, North
Chicago, IL, USA). For the quantitation of clonazepam, the
benzodiazepine assay kit was used. The detection limit for
benzodiazepine concentration in the TDx analyzer was
12 ng/ml. Thus, the analytical technique employed to
quantify clonazepam concentrations at a dose of
0.0022 mg/kg was not sensitive enough to detect clona-
zepam concentrations; therefore, the drug was evaluated at
a dose of 2.2 mg/kg (i.e., 1,000-fold higher). Total brain
antiepileptic drug concentrations are expressed in lg/ml
(except for clonazepam, whose concentrations were
expressed in ng/ml) of brain supernatants as mean ± SEM
of at least eight separate brain preparations.
Step-through passive avoidance task
The effects of WIN, classical antiepileptic drugs and their
combinations, at the ED50 values from the mouse 6 Hz test
on learning in mice were quantified by the step-through
passive avoidance task of Venault et al. (1986). On the first
day before training, each animal was administered WIN,
clonazepam, clobazam, phenobarbital, and valproate either
singly or in combination at doses corresponding to their
ED50 values from the 6 Hz test. The time before the
commencement of the training session (after drug admin-
istration) was identical to that for the 6 Hz model. Subse-
quently, animals were placed in an illuminated box
(10 9 13 9 15 cm) connected to a larger dark box
(25 9 20 9 15 cm) equipped with an electric grid floor.
Entrance of animals to the dark box was punished by an
adequate electric footshock (0.6 mA for 2 s). The animals
that did not enter the dark compartment were excluded
from subsequent experimentation (overall, 5 % of animals
used in this test) and replaced with those that correctly
performed the task. On the following day (24 h later), the
pre-trained animals were placed again into the illuminated
box and observed up to 180 s. Mice that avoided the dark
compartment for 180 s were considered to remember the
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task. The time that the mice took to enter the dark box was
noted and the median latencies (retention times) with 25th
and 75th percentiles were calculated. The step-through
passive avoidance task gives information about ability to
acquire the task (learning) and to recall the task (retrieval).
Therefore, it may be regarded as a measure of learning
(Venault et al. 1986).
Grip-strength test
The effects of WIN, classical antiepileptic drugs and their
combinations, at the ED50 values from the mouse 6 Hz test
on skeletal muscular strength in mice were quantified by
the grip-strength test of Meyer et al. (1979). The time
before the commencement of the grip-strength test (after
drug administration) was identical to that for the mouse
6 Hz test. The grip-strength apparatus (BioSeb, Chaville,
France) comprised a wire grid (8 9 8 cm) connected to an
isometric force transducer (dynamometer). The mice were
lifted by the tails so that their forepaws could grasp the
grid. The mice were then gently pulled backward by the tail
until the grid was released. The maximal force exerted by
the mouse before losing grip was recorded. The mean of
three measurements for each animal was calculated and,
subsequently, the mean maximal force of eight animals per
group was determined. The skeletal muscular strength in
mice was expressed in N (newtons) as mean ± SEM of
eight determinations.
Chimney test
The effects of WIN, classical antiepileptic drugs and their
combinations, at the ED50 values from the mouse 6 Hz test
on motor performance in mice were quantified with the
chimney test of Boissier et al. (1960). The time before the
commencement of the chimney test (after drug adminis-
tration) was identical to that for the 6 Hz test. In the
chimney test, animals had to climb backwards up a plastic
tube (30 cm length, 3 cm inner diameter). Motor impair-
ment was indicated by the inability of the animals to per-
form the test within 60 s. Results are presented as the
percentage of the mice showing motor impairment.
Statistical analysis
The ED50 values with their 95 % confidence limits were
calculated by computer log-probit analysis according to
Litchfield and Wilcoxon (1949). The obtained 95 % con-
fidence limits were transformed to standard errors of the
mean (SEM) as described previously (Luszczki et al.
2009). Microsoft’s Excel spreadsheet was used to perform
the respective calculations. This spreadsheet was pro-
grammed to compute all calculations automatically and
determine the dose–response relationship curves of the
antiepileptic drugs administered alone and in combination
with WIN from the log-probit linear regression analysis
according to Litchfield and Wilcoxon (1949). Subse-
quently, the ED50 values were statistically analyzed using
one-way analysis of variance (ANOVA) followed by the
post hoc Tukey–Kramer test for multiple comparisons.
Total brain antiepileptic drug concentrations were statisti-
cally compared using the unpaired Student’s t test. Quali-
tative variables from the chimney test were compared using
Fisher’s exact probability test. The results obtained in the
step-through passive avoidance task were statistically
evaluated using Kruskal–Wallis non-parametric ANOVA
followed by the post hoc Dunn’s multiple comparison test.
The results from the grip-strength test were verified with
one-way ANOVA followed by the post hoc Dunnett’s
multiple comparison test. Differences among values were
considered statistically significant if P \ 0.05. All
Table 1 Effect of WIN 55,212-2 mesylate on the protective activity
of various classical antiepileptic drugs against 6 Hz-induced psy-
chomotor seizures in mice
Treatment (mg/kg) ED50 (mg/kg) n
Clobazam ? vehicle 1.96 ± 0.22 24
Clobazam ? WIN (2.5) 1.62 ± 0.24 32
Clobazam ? WIN (5) 1.58 ± 0.35 32
F(2,85) = 0.4734; P = 0.6245
Clonazepam ? vehicle 0.0164 ± 0.0030 24
Clonazepam ? WIN (1.25) 0.0100 ± 0.0030 8
Clonazepam ? WIN (2.5) 0.0052 ± 0.0012** 32
Clonazepam ? WIN (5) 0.0022 ± 0.0008*** 8
F(3,68) = 7.035; P = 0.0003
Phenobarbital ? vehicle 12.72 ± 1.73 24
Phenobarbital ? WIN (2.5) 8.00 ± 1.50 32
Phenobarbital ? WIN (5) 6.49 ± 1.51* 24
F(2,77) = 3.857; P = 0.0253
Valproate ? vehicle 116.69 ± 14.37 40
Valproate ? WIN (2.5) 75.23 ± 15.10 32
Valproate ? WIN (5) 62.11 ± 10.79* 24
F(2,93) = 4.106; P = 0.0196
Results are presented as median effective doses (ED50 in mg/
kg ± SEM) of antiepileptic drugs, protecting 50 % of animals tested
against 6 Hz-induced seizures in mice. All antiepileptic drugs were
administered i.p.: phenobarbital—60 min, clobazam and valproate—
30 min and clonazepam—15 min prior to the 6 Hz-induced seizure
test. WIN 55,212-2 mesylate was administered i.p. at 20 min before
the 6 Hz-induced seizure test. Statistical analysis of the data was
performed with log-probit method and one-way ANOVA followed by
the post hoc Tukey–Kramer test for multiple comparisons. n—total
number of animals used at those doses whose anticonvulsant effects
ranged between four and six probits
* P \ 0.05; ** P \ 0.01; *** P \ 0.001 versus control (antiepileptic
drug ? vehicle-treated) animals
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statistical tests were performed using commercially avail-
able GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego, CA, USA).
Results
Effect of WIN on the anticonvulsant activity of four
classical antiepileptic drugs in the mouse 6 Hz
psychomotor seizure model
All antiepileptic drugs studied, i.e., clonazepam, clobazam,
phenobarbital and valproate displayed clear-cut anticon-
vulsant effects in the mouse 6 Hz-induced psychomotor
seizure model. The ED50 values for all antiepileptic drugs
calculated from their dose–response curves according to
the log-probit method are presented in Table 1. WIN
administered systemically (i.p.) at doses of 2.5 and 5 mg/
kg had no significant impact on the anticonvulsant effects
of clobazam in the 6 Hz test in mice (Table 1). In contrast,
WIN 2.5 and 5 mg/kg significantly enhanced the anticon-
vulsant activity of clonazepam in the 6 Hz test by reducing
its ED50 value by 68 % (P \ 0.01) and 87 % (P \ 0.001),
respectively (Table 1). Only, WIN at 1.25 mg/kg had no
significant impact on the anticonvulsant action of clona-
zepam in the mouse 6 Hz model (Table 1). Moreover,
WIN at 5 mg/kg significantly potentiated the anticonvul-
sant action of phenobarbital and valproate, by reducing the
ED50 value for phenobarbital by 49 % and for valproate by
47 %, respectively (P \ 0.05; Table 1). WIN at a lower
dose of 2.5 mg/kg had no significant effect on the anti-
convulsant action of phenobarbital and valproate against
6 Hz-induced psychomotor seizures in mice (Table 1).
Effect of WIN on total brain antiepileptic drug
concentrations
With fluorescent polarization immunoassay, total brain
concentration of clonazepam administered alone at a dose
of 2.2 mg/kg was 34.78 ± 2.02 ng/ml and did not differ
significantly from that determined when clonazepam
(2.2 mg/kg) was administered in combination with WIN
(5.0 mg/kg), which amounted to 35.19 ± 2.18 ng/ml.
Because the analytical technique employed to quantify
clonazepam concentrations at a dose of 0.0022 mg/kg was
not sensitive enough, the drug was evaluated at a dose of
2.2 mg/kg (i.e., 1,000-fold higher). Total brain concentra-
tion of phenobarbital administered alone at a dose of
6.49 mg/kg was 4.07 ± 0.12 lg/ml and did not differ
significantly from that determined for the antiepileptic drug
(6.49 mg/kg) in combination with WIN (5.0 mg/kg), which
was 4.03 ± 0.18 lg/ml. Similarly, total brain concentra-
tion of valproate administered alone at a dose of 62.11 mg/
kg was 44.91 ± 4.55 lg/ml and that of valproate
(62.11 mg/kg) in combination with WIN (5.0 mg/kg) was
48.32 ± 4.67 lg/ml, indicating no significant difference
between these concentrations with unpaired Student’s t-
test.
Influence of the antiepileptic drugs administered
in combinations with WIN on motor performance,
learning and skeletal muscular strength in the chimney,
passive avoidance and grip-strength tests
In case of WIN administered alone at the dose of 5 mg/kg,
it was found that the non-specific cannabinoid CB1 and
CB2 receptor agonist had no significant impact on motor
coordination in the chimney test, learning in the passive
avoidance task or skeletal muscular strength in the grip-
strength test in mice (Table 2). When WIN (5 mg/kg) was
administered in combination with clobazam, clonazepam,
phenobarbital and valproate (at doses corresponding to
their ED50 values from the 6 Hz test), it did not impair
motor coordination or learning or affect muscular skeletal
strength as assessed by the chimney test, passive avoidance
task and grip-strength test, respectively (Table 2).
Discussion
Results presented herein indicate that WIN enhanced the
anticonvulsant action of clonazepam, phenobarbital and
valproate, but not that of clobazam in the mouse 6 Hz-
induced psychomotor seizure test. The selection of classi-
cal antiepileptic drugs (i.e., clobazam, clonazepam, phe-
nobarbital and valproate) in this study was based on
information that these antiepileptic drugs suppressed, in a
dose dependent manner, the 6 Hz-induced psychomotor
seizures in mice (Barton et al. 2001; Rowley and White
2010; Smith et al. 2007). In contrast, some classical and
second-generation antiepileptic drugs, i.e., carbamazepine,
phenytoin, topiramate and vigabatrin, are virtually inef-
fective in this seizure model (Florek-Luszczki et al. 2014)
and, therefore, these antiepileptic drugs were not tested in
the presented study.
It is worth mentioning that WIN administered alone at
doses up to 5 mg/kg did not protect any animals against
6 Hz-induced psychomotor seizures. This is the reason that
WIN was administered in the presented study at doses up to
5 mg/kg when combined with each of the selected classical
antiepileptic drugs.
The results presented herein confirm our previous
observations showing that WIN significantly enhanced the
anticonvulsant action of phenobarbital and valproate
(Table 3; Luszczki et al. 2011a, b). Previously, it has been
documented that WIN at 15 mg/kg significantly
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potentiated the anticonvulsant action of phenobarbital and
valproate in the mouse PTZ-induced seizure test (Table 3;
Luszczki et al. 2011a). Unfortunately, WIN at lower doses
of 5 and 10 mg/kg had no impact on the anticonvulsant
action of phenobarbital and valproate in the mouse PTZ-
induced clonic seizure model (Luszczki et al. 2011a). In the
mouse MES model, WIN 10 mg/kg significantly potenti-
ated the anticonvulsant action of phenobarbital and val-
proate. Similarly, WIN 5 mg/kg also potentiated the
antiseizure action of valproate, but not that of phenobar-
bital in the mouse MES model (Table 3; Luszczki et al.
2011b). In the presented study, WIN 5 mg/kg significantly
enhanced the anticonvulsant action of phenobarbital and
valproate in the mouse 6 Hz-induced psychomotor seizure
model. In contrast, WIN at a dose of 2.5 mg/kg had no
impact on the anticonvulsant action of phenobarbital and
valproate in the 6 Hz model.
Moreover, it was documented herein that WIN at doses
of 2.5 and 5 mg/kg significantly potentiated the anticon-
vulsant action of clonazepam in the mouse 6 Hz psycho-
motor seizure test. In contrast, WIN (at doses up to 15 mg/
kg) did not affect the anticonvulsant action of clonazepam
in the mouse PTZ-induced clonic seizure model (Table 3;
Luszczki et al. 2011a). The observed discrepancy could be
explained through different seizure models used. Since
molecular mechanisms of action of clonazepam and WIN
were the same in both 6 Hz and PTZ tests, the apparent
difference in the antiseizure activity of clonazepam after
administration of WIN must result from diverse induction
of seizure activity in animals (i.e., electrically vs. chemi-
cally evoked seizures).
In the case of clobazam, WIN did not significantly affect
the anticonvulsant action of the antiepileptic drug in the
6 Hz model. In contrast, WIN 2.5 and 5 mg/kg signifi-
cantly enhanced the anticonvulsant action of clobazam in
the mouse MES model (unpublished data, Table 3). Simi-
larly, since molecular mechanisms of action of clobazam
and WIN were the same in both 6 Hz and MES tests, the
apparent difference in the antiseizure activity of clobazam
after administration of WIN must result from diverse
induction of seizure activity in animals (i.e., electrically
evoked seizures).
Of note, a substantial difference in pharmacological
action of clonazepam and clobazam after administration of
WIN in the 6 Hz model was observed. Considering
molecular mechanisms of action of clobazam and
Table 2 Effects of WIN 55,212-2 mesylate in combinations with four classical antiepileptic drugs on learning, muscular strength and motor
performance in mice
Treatment (mg/kg) Retention time (s) Grip-strength (N) Motor coordination
impairment (%)
Vehicle 180 (180; 180) 0.92 ± 0.04 0
WIN (5.0) ? vehicle 173.5 (155; 180) 0.91 ± 0.04 25
Clobazam (1.58) ? WIN (5.0) 180 (180; 180) 0.90 ± 0.05 12.5
Clonazepam (0.0022) ? WIN (5.0) 180 (180; 180) 0.91 ± 0.05 0
Phenobarbital (6.49) ? WIN (5.0) 180 (180; 180) 0.90 ± 0.04 12.5
Valproate (62.11) ? WIN (5.0) 180 (155.8; 180) 0.90 ± 0.05 25
Results are presented as: (1) median retention times (in seconds; with 25th and 75th percentiles in parentheses) from the passive avoidance task,
assessing learning in mice; (2) mean grip-strengths (in Newtons ± SEM) from the grip-strength test, assessing skeletal muscular strength in
mice; and (3) percentage of animals showing motor coordination impairment in the chimney test in mice. Each experimental group consisted of
eight mice. Statistical analysis of the data from the passive avoidance task was performed with non-parametric Kruskal–Wallis ANOVA test.
Results from the grip-strength test were analyzed with one-way ANOVA. The Fisher’s exact probability test was used to analyze the results from
the chimney test. All drugs were administered i.p. at specific pretreatment times scheduled from the 6 Hz-induced psychomotor seizures and at
doses corresponding to their ED50 values against 6 Hz-induced convulsions in mice (for more details see the legend to Table 1)
Table 3 Influence of WIN 55,212-2 mesylate on the anticonvulsant





MES PTZ 6 Hz
Clobazam : (2.5 and
5 mg/kg)a
N.T. 0 (5 mg/kg)d
Clonazepam N.T. 0 (15 mg/kg)c : (2.5 and
5 mg/kg)d
Phenobarbital : (10 mg/kg)b : (15 mg/kg)c : (5 mg/kg)d
Valproate : (10 mg/kg)b : (15 mg/kg)c : (5 mg/kg)d
Doses of WIN, which significantly potentiated the anticonvulsant
activity of the studied antiepileptic drugs, are given in parentheses
MES—maximal electroshock-induced seizure test, PTZ—pentylene-
tetrazole-induced seizure test, 6 Hz—psychomotor (limbic) 6 Hz-
induced seizure test, :—increase in the anticonvulsant activity of the
studied antiepileptic drug, 0—no significant effect despite the
administration of WIN at a maximally tested dose, N.T.—not tested
a unpublished data
b Results from Luszczki et al. 2011b
c Results from Luszczki et al. 2011a
d Results from this study
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clonazepam, it can be ascertained that both drugs sub-
stantially differ from one another. Although, both antiepi-
leptic drugs are benzodiazepines and both evoke GABAA
receptor-mediated suppression of seizures, clonazepam and
clobazam must differ in relation to their intrinsic activity
on GABAA receptors after WIN administration. Bearing in
mind a substantial difference in the action of clonazepam
and clobazam after co-administration of WIN in the mouse
6 Hz model, one can suggest that clonazepam is more
active than clobazam in this seizure model (Table 3). On
comparing results presented in Table 3, one can ascertain
that WIN potentiated the anticonvulsant action of clona-
zepam in the 6 Hz model and clobazam in the mouse MES
model, remaining almost inactive when combined with
clonazepam in the mouse PTZ model and with clobazam in
the 6 Hz model. Thus, the influence of WIN seems to be
specific for seizure model used in experimental studies.
Of note, clobazam (7-chloro-1-methyl-5-phenyl-1,5-
benzodiazepine-2,4-dione), in contrast to clonazepam (5-
(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-
one), has a 1,5 substitution instead of the usual 1,4-ben-
zodiazepine structure, which results in a reduction of the
sedative effects without losing its anticonvulsant effects
(Schmidt 2002). Generally, clobazam is better tolerated
than other benzodiazepines. This is the reason for clobazam
being used as an excellent second-line therapy in some
patients with resistant epilepsy (Schmidt 2002). With
regard to clobazam, it enhances GABAergic activity by
binding to the a subunit of the GABAA receptor and
increasing the frequency of chloride channel conductance
by allosteric activation of the GABAA receptor (Ng and
Collins 2007). Moreover, clobazam increases expression of
glutamate transporter protein 1 (GLT1) and GABA trans-
porter protein 3 (GAT3) in the brain (Doi et al. 2005). In
case of clonazepam, the drug as a benzodiazepine works by
primarily enhancing GABAergic inhibition by binding to
the benzodiazepine receptor on GABAA receptors (Patsalos
2005).
The apparent difference in the anticonvulsant action of
clobazam and clonazepam after WIN administration in the
6 Hz seizure model may result from their different affinity
to benzodiazepine receptors in the brain. Although this
hypothesis is highly speculative, it can readily explain the
observed difference in the anticonvulsant activity of the
drugs after administration of WIN. To confirm or reject this
hypothesis, more advanced molecular studies are required.
It is highly likely that WIN-related activation of can-
nabinoid CB1 and CB2 receptors potentiated clonazepam-
induced activation of GABAA receptors in the brains of
experimental animals subjected to 6 Hz-induced psycho-
motor (limbic) seizures, and thus, a favorable combination
by suppressing 6 Hz-induced psychomotor seizures in mice
can be reported. With regard to WIN and its interaction
with GABAA receptors, it has been found in in vitro studies
that WIN decreased the cumulative amplitude of inhibitory
postsynaptic currents (IPSCs) with maximal inhibition
observed at 20 min after WIN administration (Kovacs et al.
2012). WIN inhibited GABAergic synaptic transmission by
activating cannabinoid CB1 receptors at the presynaptic
axon terminals and did not modify the effect of released
GABA on the postsynaptic neurons (Kovacs et al. 2012).
In contrast, AM251 (1-(2,4-dichlorophenyl)-5-(4-io-
dophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxam-
ide—a cannabinoid CB1 receptor antagonist) and
rimonabant (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide—a
cannabinoid CB1 receptor inverse agonist) allosterically
potentiate GABAA receptors expressed in Xenopus oocytes
at nM concentrations (Baur et al. 2012). The site of action
of AM251 and rimonabant is not identical to that of ben-
zodiazepines, loreclezole, phenobarbital or neurosteroids
(Baur et al. 2012). Experimental evidence indicates that the
endogenous cannabinoid 2-arachidonoyl glycerol potenti-
ates GABAA receptors containing b2 subunit, at low con-
centrations of GABA (Sigel et al. 2011, Baur et al. 2013).
Since 2-arachidonoyl glycerol is biosynthesized in post-
synaptic neurons, the endocannabinoid interacts locally
with GABAA receptors within the postsynaptic neurons
(Sigel et al. 2011). Additionally, it has been documented in
in vitro study that 2-arachidonoyl glycerol interacted supra-
additively (synergistically) with 3a,21-dihydroxy-5a-
pregnan-20-one (a neurosteroid) and diazepam (a benzo-
diazepine), suggesting that this endocannabinoid modulates
the action of neurosteroids and benzodiazepines at extra-
synaptic and synaptic b2 subunit-containing GABAA
receptors (Sigel et al. 2011). Considering the above-dis-
cussed facts, it is highly likely that WIN, despite the
inhibition of GABAergic synaptic transmission at presyn-
aptic neuronal terminals, enhances response of GABAA
receptors in postsynaptic neurons. Since supra-additive
interaction has been documented in vitro between
2-arachidonoyl glycerol (an endogenous cannabinoid) and
diazepam (a benzodiazepine), it is highly likely that WIN
can also supra-additively interact with clonazepam in
in vivo experiments.
With regard to acute adverse effects produced by the
antiepileptic drugs in combination with WIN, it can be
ascertained that all the studied antiepileptic drugs admin-
istered either alone or in combination with WIN (at doses
corresponding to their ED50 values from the 6 Hz test) did
not exert acute adverse effects as determined in the
chimney, passive avoidance and grip-strength tests in mice.
Previously, we reported that WIN administered either alone
or in combination with various antiepileptic drugs (at doses
corresponding to the ED50 values of the tested antiepileptic
drugs) significantly impaired motor coordination in the
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chimney test, disturbed learning processes in the passive
avoidance task and alleviated muscular strength in the grip-
strength test in mice (Luszczki et al. 2011a, b). More
specifically, it has been documented that WIN administered
alone at a dose of 10 mg/kg significantly reduced skeletal
muscular strength in mice subjected to the grip-strength
test (Luszczki et al. 2011b). Likewise, WIN (10 mg/kg)
combined with carbamazepine, phenobarbital, phenytoin
and valproate (at doses corresponding to the ED50 values
from the MES test) considerably reduced skeletal muscular
strength in mice (Luszczki et al. 2011b). In the step-
through passive avoidance task, WIN combined with phe-
nobarbital, phenytoin and valproate significantly disturbed
learning in mice (Luszczki et al. 2011b). In the chimney
test, WIN combined with phenobarbital and valproate
significantly impaired motor performance in mice (Lus-
zczki et al. 2011b). Similar results were observed when
WIN (15 mg/kg) was combined with clonazepam, etho-
suximide, phenobarbital and valproate. More specifically,
all combinations of WIN (15 mg/kg) with clonazepam,
ethosuximide, phenobarbital and valproate (at doses cor-
responding to the ED50 values from the PTZ-induced sei-
zure test) significantly impaired learning in the passive
avoidance task, reduced skeletal muscular strength in the
grip-strength test and impaired motor coordination in the
chimney test (Luszczki et al. 2011a). However, in the
present study, no significant changes in motor performance,
learning and muscular strength were observed in mice
because of a low dose of WIN used (5 mg/kg). Of note, the
observed slight impairment of motor coordination in mice
receiving WIN alone or WIN in combination with the
studied antiepileptic drugs (up to 25 %) was not significant
with the Fisher’s exact probability test. Thus, the combi-
nations of WIN with the tested antiepileptic drugs are
worthy of consideration when used in patients.
Moreover, pharmacokinetic evaluation of total brain
antiepileptic drugs concentrations revealed that WIN 5 mg/
kg did not affect total brain concentrations of clonazepam,
phenobarbital and valproate in experimental animals. Our
pharmacokinetic study is consistent with that documenting
earlier that WIN did not affect total brain concentrations of
phenobarbital and valproate in mice (Luszczki et al. 2011a,
b). On the other hand, because there were no pharmaco-
kinetic changes in total brain concentrations of clonaze-
pam, phenobarbital and valproate after co-administration of
WIN, it can be ascertained that the enhanced anticonvul-
sant action of clonazepam, phenobarbital and valproate in
the 6 Hz model was a result of pharmacodynamic inter-
actions between the tested drugs. Because WIN did not
significantly affect the protective action of clobazam
against 6 Hz-induced psychomotor seizures, we did not
estimate the total brain concentrations of the antiepileptic
drug in mice. However, it can be assumed that since WIN
did not affect total brain concentrations of clonazepam,
phenobarbital and valproate in mice, the non-selective
cannabinoid CB1 and CB2 receptor agonist (WIN) would
not affect total brain concentrations of clobazam.
Conclusions
Based on this preclinical study, it can be concluded that the
combinations of WIN with clonazepam, phenobarbital and
valproate can potentially offer patients with limbic seizures
favorable combinations and worthy of clinical evaluation.
In all cases, because a substantial dose reduction of anti-
epileptic drugs in the mixture can be anticipated, it can be
expected that concurrent adverse effects would be signifi-
cantly reduced and this is a clinically desirable outcome.
Since WIN had no impact on clobazam’s anticonvulsant
action in the 6 Hz model, this combination should not be
recommended for patients with epilepsy. If the results from
this study could be extrapolated into clinical settings, a
novel therapeutic option in the treatment of limbic epilepsy
would be created.
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